Clinical Report: Nirsevimab may curb RSV severity
Overview
Nirsevimab demonstrates effectiveness against RSV-related hospitalizations among infants during the first season of universal immunization in Canada, with an overall effectiveness of 78%.
Background
Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in infants, significantly impacting healthcare resources. Effective prevention strategies are crucial in reducing RSV-related morbidity and mortality in this vulnerable population.
Data Highlights
| Care Setting | Effectiveness (%) |
|---|---|
| Overall | 78 |
| Emergency Department Visits | 77 |
| Inpatient Hospitalization | 79 |
| ICU Admission | 97 |
Key Findings
- Overall nirsevimab effectiveness against laboratory-confirmed RSV was 78%.
- Effectiveness was 77% against emergency department visits and 79% against inpatient hospitalization.
- Effectiveness was 97% against ICU admissions.
- Estimated effectiveness was 90% among infants born prematurely.
- Effectiveness decreased over time: 85% at 7-29 days, 69% at 30-59 days, and 78% at 60-89 days post-administration.
Clinical Implications
Clinicians should consider the timing and administration of nirsevimab as part of RSV prevention strategies.
Conclusion
Nirsevimab shows effectiveness in reducing RSV-related hospitalizations among infants.
Related Resources & Content
- Buchan SA, et al., JAMA Network Open, 2025 -- Nirsevimab may curb RSV severity
- MDSpire News, 2025 -- Nirsevimab Shows 83% Efficacy Over 6 Months
- MDSpire News, 2025 -- Nirsevimab Linked to Lower Infant Hospitalization Risk Than Maternal Vaccine
- American Academy of Pediatrics, 2025 -- Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children
- JAMA Network Open — Nirsevimab and a Community Recall-Based Immunization Strategy for Child Bronchiolitis Prevention
- JAMA Pediatrics — Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations
- CDC -- Respiratory Syncytial Virus (RSV) Vaccine Safety
- Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Policy Statement | Pediatrics | American Academy of Pediatrics
- Respiratory Syncytial Virus–Related Hospitalizations Among Infants Receiving Nirsevimab | Public Health | JAMA Network Open | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
